Literature DB >> 25638762

Diversity of breakpoints of variant Philadelphia chromosomes in chronic myeloid leukemia in Brazilian patients.

Maria de Lourdes Lopes Ferrari Chauffaille1, Ana Carolina de Almeida Bandeira2, Aline Schiavoni Guarnieri da Silva3.   

Abstract

BACKGROUND: Chronic myeloid leukemia is a myeloproliferative disorder characterized by the Philadelphia chromosome or t(9;22)(q34.1;q11.2), resulting in the break-point cluster region-Abelson tyrosine kinase fusion gene, which encodes a constitutively active tyrosine kinase protein. The Philadelphia chromosome is detected by karyotyping in around 90% of chronic myeloid leukemia patients, but 5-10% may have variant types. Variant Philadelphia chromosomes are characterized by the involvement of another chromosome in addition to chromosome 9 or 22. It can be a simple type of variant when one other chromosome is involved, or complex, in which two or more chromosomes take part in the translocation. Few studies have reported the incidence of variant Philadelphia chromosomes or the breakpoints involved among Brazilian chronic myeloid leukemia patients.
OBJECTIVE: The aim of this report is to describe the diversity of the variant Philadelphia chromosomes found and highlight some interesting breakpoint candidates for further studies.
METHODS: the Cytogenetics Section Database was searched for all cases with diagnoses of chronic myeloid leukemia during a 12-year period and all the variant Philadelphia chromosomes were listed.
RESULTS: Fifty (5.17%) cases out of 1071 Philadelphia-positive chronic myeloid leukemia were variants. The most frequently involved chromosome was 17, followed by chromosomes: 1, 20, 6, 11, 2, 10, 12 and 15.
CONCLUSION: Among all the breakpoints seen in this survey, six had previously been described: 11p15, 14q32, 15q11.2, 16p13.1, 17p13 and 17q21. The fact that some regions get more frequently involved in such rare rearrangements calls attention to possible predisposition that should be further studied. Nevertheless, the pathological implication of these variants remains unclear.
Copyright © 2014 Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published by Elsevier Editora Ltda. All rights reserved.

Entities:  

Keywords:  Brazil; Chromosome breakpoints; Leukemia, myelogenous, chronic, BCR-ABL positive; Oncogenes; Philadelphia chromosome

Year:  2014        PMID: 25638762      PMCID: PMC4863423          DOI: 10.1016/j.bjhh.2014.07.006

Source DB:  PubMed          Journal:  Rev Bras Hematol Hemoter        ISSN: 1516-8484


Introduction

Chronic myeloid leukemia (CML) is a myeloproliferative disorder characterized by the presence of the Philadelphia chromosome (Ph) which is the derivative chromosome 22 of the translocation t(9;22)(q34.1;q11.2). Due to this rearrangement, the break-point cluster region (BCR) gene at position 22q11.2 is juxtaposed to the c-Abelson (ABL1) gene at 9q34, resulting in the BCR-ABL1 fusion gene, encoding a constitutively active tyrosine kinase protein. The identification of this abnormality is important for the diagnosis of the disease as determined by the WHO Tumor Classification and for treatment purposes. The first therapeutic choice, tyrosine kinase inhibitors, has shown great therapeutic efficacy. The Ph is detected by G-band karyotyping in around 90% of CML patients among whom 5–10% may have variant types.3, 4, 5 Variant Ph chromosomes are characterized by the involvement of another chromosome in addition to chromosome 9 or 22. It can be a simple type of variant when only one additional chromosome is involved, or complex, in which two or more chromosomes, besides chromosomes 9 and 22, take part in the translocation.6, 7 Variant Ph breakpoints occur in hotspots across the genome, usually in the G-light bands, within the cytosine and guanine (CG) rich parts of the genome. CG content correlates with chromatin condensation and transcription activity; that is, open chromatin is transcriptionally active and relatively likely to undergo breakage and repair with a consequent tendency to illegitimate recombination and translocation. The 3′ portion of the BCR gene recombines preferentially with Alu elements at the breaks. However, the mechanism of variant Ph generation and the molecular bases of biological differences between classic Ph and variant Ph chromosomes are not fully understood. Recently, Albano et al. reported a study they performed on gene expression profiling (GEP) using microarrays to identify some of these differences. They found 59 genes showing differential expressions. Some of them (TR1B1, PTK2B and C5AR1) were involved in the MAPK pathway, which is already known to play a role in CML pathogenesis. The prognostic significance of variant Ph chromosomes has already been discussed, and it has been shown that the variant aberration does not impact on cytogenetic or molecular responses or even on clinical outcome. Variant Ph chromosomes are distinguished from additional chromosomal abnormalities or clonal evolution that drives disease progression. The clonal evolution is a reflection of a genetic instability that characterizes the transition to advanced phase. In this situation, i(17q), a second Ph and +8 are frequently found. Few studies have reported the incidence of variant Ph chromosomes, or the breakpoints involved, in Brazilian CML patients.13, 14

Objective

The aim of this report is to describe the diversity of variant Ph chromosomes found in a group of Brazilian CML patients and to highlight some interesting breakpoint candidates for further studies.

Methods

A search was conducted of variant Ph chromosomes among all the cases of CML in the Cytogenetics Section Database of Fleury Laboratory (São Paulo, Brazil), during a 12-year period (from 1999 to 2010). The diagnosis of CML was made according to WHO Tumor Classification, with analysis of complete blood count, marrow aspiration and/or biopsy and karyotyping. Acute myeloid or lymphoid leukemia cases were excluded. Karyotype analyses were performed from marrow samples, through non-stimulated short term cultures and classified according to the International System for Human Cytogenetics Nomenclature (ISCN). CML cases with positive BCR-ABL1 detection by fluorescent in situ hybridization (FISH) or polymerase chain reaction (PCR) at diagnosis, but with cryptic rearrangements by karyotyping, were excluded from the study since they were cytogenetically invisible. The study was approved by the Institution Ethics Committee.

Results

Fifty cases (5.17%) of variant t(9;22) were found out of 1071 Ph-positive CML. Table 1 shows the list of the variant Philadelphia translocation cases (some of these cases were previously reported) and Table 2 shows the rearrangement breakpoints. A total of 33 different regions and almost all chromosomes were involved in rearrangements, except for chromosomes: 8, 9, 18, 21, 22, X and Y. In two cases it was not possible to identify the extra chromosome of the variant translocation.
Table 1

List of the variant Philadelphia translocations found.

CaseKaryotypeType of translocation
146,XY,t(1;9;22;16)(q32;q34.1;q11.2;p13)[2]/46,XYComplex
246,XX,t(9;22;1;13)(q34.1;q11.2;p12;q34)[17]/46,XX[3]Complex
346,XY,t(9;22;1;?3)(q34.1;q11.2;q36.3;?q26)[20]Complex
446,XX,t(1;9;22;14)(p21;q34.1;q11.2;q32)[20]Complex
546,XX,t(9;22;1)(q34.1;q11.2;p34)[20]Simple
646,XX,t(9;22;1)(q34.1;q11.2;p36.3)[19]/46,XX[1]Simple
746,XX,t(9;22;2)(q34.1;q11.2;q37)[20]Simple
846,XY,t(2;9;22)(p21;q34.1;q11.2)[20]Simple
946,XY,t(9;22;2)(q34.1;q11.2;q24)[8]/46,XY[12]Simple
1046,XY,t(9;22;4)(q34.1;q11.2;p16)[20]Simple
1146,XY,t?(9;22;10;11)(q34.1;q11.2;q22;q25)[20]Complex
1246,XY,t(9;22;5)(q34.1;q11.2;p13)[20]Simple
1346,XY,t(9;22;6)(q34.1;q11.2;q22)Simple
1446,XX,t(9;22;6)(q34.1;q11.2;q27)[7]/46,idem,?del(12)(p11.2p13)[3]/46,XX[10]Simple
1546,XY,t(9;22;6)(q34.1;q11.2;q22)Simple
1646,XY,t(9;22;15)(q34.1;q11.2;q11.2)[20]Simple
1746,XX,t(9;22;7)(q34.1;q11.2;p22)[20]Simple
1846,XX,t(?9;22;7)(q34.1;q11.2;q36), 9phqh[14]/46,XX, 9phqh[6]Simple
1946,XY,t(9;22;10)(q34.1;q11.2;q21)[17]/46,XY[3]Simple
2046,XY,t?(9;22;10;11)(q34.1;q11.2;q22;q25)[20]Complex
2146,XY,t(9;22;4)(q34.1;q11.2;p16)[1]/45,idem,add(7)(p22),-8[18]/46,XY[1]Simple
2244∼45,XX,t(7;12)(q11.2;p12),?t(9;22;11)(q34.1;q11.2;p15),-14,-15,1min[cp18]/46,XX[2]Simple
2346,XY,t(9;22;11)(q34.1;q11.2;p15),9ph[20]Simple
2446,XX,t(9;?22;12)(q34.1;?q11.2;q24)[17]/46,XX[3]Simple
2546,XY,t(1;7)(p22;q22),t(9;22;20)(q34.1;q11;q11.2)[4]/46,XY,t(9;22;20)(q34.1;q11;q11.2)[3]Simple
2646,XY,t(9;22;12)(q34.1;q11.2;p13)[20]Simple
2746,XY,t(9;22;14)(q34.1;q11.2;q32)[19]/46,XY[1]Simple
2846,XY,t(9;22;15)(q34.1;q11.2;q25),t(17;19)(q12;q13.4)[20]Simple
2946,XY,t(9;22;15)(q34.1;q11.2;q11.2)[20]Simple
3046,XX,t(9;22;6)(q34.1;q11.2;q27)[7]/46,idem,?del(12)(p11.2p13)[3]/46,XX[14]Simple
3146,XX,t?(9;22;16)(q34.1;q11.2;p13.3)[20]Simple
3246,XX,t(9;22;17)(q34.1;q11.2;q21?)[14]/46,XX[6]Simple
3346,XX,t(9;22;17)(q34.1;q11.2;q?21)[16]/46,XX[4]Simple
3446,XY,t(9;22;17)(q34.1;q11.2;q21)[20]Simple
3546,XX,t(9;22;17)(q34.1;q11.2),t(12;13)(q13;p11)[20]Simple
3646,XY,t(9;22;17)(q34.1;q11.2;p13)[20]Simple
3746,XX,t(9;22;17)(q34.1;q11.2;q24)[20]Simple
3846,XY,t(9;22;17)(q34.1;q11.2;p13)[20]Simple
3946,XX,t(9;22;17)(q34.1;q11.2;q21)[10]//46,XX[10]Simple
4046,XY,t(9;22;17)(q34.1;q11.2;p13)[3]/75∼77,XY,+X,+1,+5,+6,+9,t(9;22;17)(q34.1;q11.2;p13)x2,+10,+11,+12,+20,+21,+22[cp16]/46,XY[1]Simple
4146,XX,t(9;22;17)(q34.1;q11.2;q24)[1]/47,XX,+8[8]/46,XX[11]Simple
4246,XY,t(1;7)(p22;q22),t(9;22;20)(q34.1;q11;q11.2)[20]Simple
4346,XY,t(9;22;19)(q34.1;q11.2;q11.2)[20]Simple
4446,XY,t(9;22;20)(q34.1;q11.2;q11.2)[13]/46,XY,t(1;7)(p22;q22),idem[7]Simple
4546,XY,t(1;7)(p22;q22),t(9;22;20)(q34.1;q11;q11.2)[2]/46,XY[18]Simple
4646,XX,t(9;22;17)(q34.1;q11.2;q24)[1]/47,XX,+8[11]/46,XX[8]Simple
4746,XY,t(9;22;12)(q34.1;q11.2;q24.3)[20]Simple
4846,XY,t(1;7)(p22;q22),t(9;22;20)(q34.1;q11;q11.2)[1]/46,XY[9]Simple
4946,XY,t(9;22;?)(q34.1;q11.2;?)[11]/46,XY[9]Simple
5046,XY,t(9;22;?)(q34.1;q11.2;?)[20]Simple
Table 2

List of regions involved in Ph variant translocations.

Chromosome region
1p342q3710q2115q11.2
1p36.33q2610q2215q25
1q11.24p1611p1516p13
1q125p1311q2517p13
1q326q2212p1317q21
1q36.36q2712q2417q24
2p217p2213q3419q11.2
2q247q3614q3220q11.2

Discussion

The incidence of variant Ph chromosomes in Brazilian CML patients was similar to published data (5.17%). Forty-four (88%) were simple variants and six (12%) complex (Table 1), also in accordance with previous reports. The most frequently involved chromosome was 17 (eleven times more common in the present report), followed by chromosome 1 (six times), 20 (five times), 6, 11 (four times each), and 2, 10, 12 and 15 (three times each). Marzocchi et al. reported four cases of the involvement of chromosome 17 out of 30 variants. The chromosomes not involved in Ph variant translocations in the present study were: 8, 9, 18, 21, 22, X and Y, while other studies have shown rearrangements of these chromosomes, except for Y.14, 17, 18 Among all breakpoints seen in this survey, six were repeated: 11p15, 14q32, 15q11.2, 16p13.1, 17p13 and 17q21, differing from the report by Marzocchi et al. who did not find any recurrent breakpoints. On the other hand, Reid et al. listed nine recurring breakpoints in variant Ph translocations, most of which had been reported by others. In fact, it seems that most breakpoints related to variant Ph chromosomes occur in regions of known oncogenes or typical secondary breakpoints in other types of cancer. Indeed, we endorse this statement, since the current study also identified some breakpoints common to other cancers, such as 12p13, 17p13 and 17q21. Some of the genes located in these regions are related to hematological malignancies (i.e. ETV6, CD9, RARA, GAS7, IGH-2, MYB). However, additional genes have already been reported in respect to CML, including TP53, located at 17p13, and involved in up to 30% of CML cases in blast crisis and MECOM and VRK1 that play a role in blast crises. Moreover, it is also known that the BCR-ABL1 tyrosine kinase activity activates the P13K/AKT signaling pathway. Thus, more studies regarding the function, expression and regulation of these and other genes may help to explain how variant Ph translocations occur. Controversies were found in respect to the meaning of variant Ph chromosomes. Some authors have stated that the involvement of additional oncogenes could be associated to poorer prognosis although the European LeukemiaNet recommendations do not provide advice for patients with variant translocations.2, 5 In the tyrosine kinase inhibitors era, it seems that variant Ph translocations have no implication on the prognosis, evolution of the disease and response to treatment.5, 18

Conclusions

Due to the large variety of Ph variant translocations, it seems that many possible interactions exist with some occurring in regions already reported as hotspots of oncogenes or related to different types of cancer. This suggests that there must be local phenomena favoring the predisposition to the involvement of these breakpoints. The incidence of Ph variant translocations in Brazilian patients is similar to other reports worldwide however some new variants were found. 17q21 was the most frequent and repeated breakpoint and so this region is the most likely to be involved in Ph variant translocations. Nevertheless, the pathological implication of these variants remains unclear.

Conflicts of interest

The authors declare no conflicts of interest.
  15 in total

1.  Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysis.

Authors:  Giulia Marzocchi; Fausto Castagnetti; Simona Luatti; Carmen Baldazzi; Monica Stacchini; Gabriele Gugliotta; Marilina Amabile; Giorgina Specchia; Mario Sessarego; Ursula Giussani; Laura Valori; Giancarlo Discepoli; Anna Montaldi; Alessandra Santoro; Laura Bonaldi; Giovanni Giudici; Anna Maria Cianciulli; Francesca Giacobbi; Francesca Palandri; Fabrizio Pane; Giuseppe Saglio; Giovanni Martinelli; Michele Baccarani; Gianantonio Rosti; Nicoletta Testoni
Journal:  Blood       Date:  2011-03-29       Impact factor: 22.113

2.  The Philadelphia chromosome. Considerations based on studies of variant Ph translocations.

Authors:  T Ishihara; M Minamihisamatsu
Journal:  Cancer Genet Cytogenet       Date:  1988-05

3.  Breakpoints of variant 9;22 translocations in chronic myeloid leukemia locate preferentially in the CG-richest regions of the genome.

Authors:  Andrew M Fisher; Paul Strike; Claire Scott; Anthony V Moorman
Journal:  Genes Chromosomes Cancer       Date:  2005-08       Impact factor: 5.006

4.  The BCR gene recombines preferentially with Alu elements in complex BCR-ABL translocations of chronic myeloid leukaemia.

Authors:  A R Jeffs; S M Benjes; T L Smith; S J Sowerby; C M Morris
Journal:  Hum Mol Genet       Date:  1998-05       Impact factor: 6.150

5.  Survival implications of molecular heterogeneity in variant Philadelphia-positive chronic myeloid leukaemia.

Authors:  Alistair G Reid; Brian J P Huntly; Colin Grace; Anthony R Green; Elisabeth P Nacheva
Journal:  Br J Haematol       Date:  2003-05       Impact factor: 6.998

6.  Cytogenetic response to imatinib treatment in Southern Brazilian patients with chronic myelogenous leukemia and variant Philadelphia chromosome.

Authors:  Dayane B Koshiyama; Marcelo E Z Capra; Giorgio A Paskulin; Rafael F M Rosa; Ceres A V Oliveira; Tito Vanelli; Laura M Fogliatto; Paulo R G Zen
Journal:  Ann Hematol       Date:  2012-10-14       Impact factor: 3.673

Review 7.  Molecular biology of bcr-abl1-positive chronic myeloid leukemia.

Authors:  Alfonso Quintás-Cardama; Jorge Cortes
Journal:  Blood       Date:  2008-09-30       Impact factor: 22.113

8.  Results of imatinib mesylate therapy in chronic myelogenous leukaemia with variant Philadelphia chromosome.

Authors:  Maha M T El-Zimaity; Hagop Kantarjian; Moshe Talpaz; Susan O'Brien; Francis Giles; Guillermo Garcia-Manero; Srdan Verstovsek; Deborah Thomas; Alessandra Ferrajoli; Kimberly Hayes; B Nebiyou Bekele; Xian Zhou; Mary B Rios; Armand B Glassman; Jorge E Cortes
Journal:  Br J Haematol       Date:  2004-04       Impact factor: 6.998

9.  Complex Variant t(9;22) Chromosome Translocations in Five Cases of Chronic Myeloid Leukemia.

Authors:  Ana Valencia; José Cervera; Esperanza Such; Eva Barragán; Pascual Bolufer; Oscar Fuster; Rosa Collado; Jesús Martínez; Miguel A Sanz
Journal:  Adv Hematol       Date:  2009-07-28

10.  Gene expression profiling of chronic myeloid leukemia with variant t(9;22) reveals a different signature from cases with classic translocation.

Authors:  Francesco Albano; Antonella Zagaria; Luisa Anelli; Nicoletta Coccaro; Luciana Impera; Crescenzio Francesco Minervini; Angela Minervini; Antonella Russo Rossi; Giuseppina Tota; Paola Casieri; Giorgina Specchia
Journal:  Mol Cancer       Date:  2013-05-04       Impact factor: 27.401

View more
  5 in total

1.  Cytogenetic and Molecular Analyses of Philadelphia Chromosome Variants in CML (chronic myeloid leukemia) Patients from Sindh using Karyotyping and RT-PCR.

Authors:  Ikram Din Ujjan; Anwar Ali Akhund; Muhammad Saboor; Muhammad Asif Qureshi; Saeed Khan
Journal:  Pak J Med Sci       Date:  2015 Jul-Aug       Impact factor: 1.088

2.  Is karyotyping still needed in the diagnosis and monitoring of chronic myeloid leukemia?

Authors:  Maria de Lourdes L F Chauffaille
Journal:  Rev Bras Hematol Hemoter       Date:  2017-02-21

Review 3.  A unique three-way Philadelphia chromosome variant t(4;9;22)(q21;q34;q11.2) in a newly diagnosed patient with chronic phase chronic myeloid leukemia: a case report and review of the literature.

Authors:  Yuka Torii; Kana Nanjo; Tomomi Toubai; Masashi Hosokawa; Ryo Sato; Akane Yamada; Keiko Aizawa; Masahito Himuro; Satoshi Ito; Masakazu Yamamoto; John Magenau; Ryan Wilcox; Kenichi Ishizawa
Journal:  J Med Case Rep       Date:  2021-05-25

Review 4.  The spectrum of chromosomal translocations in the Arab world: ethnic-specific chromosomal translocations and their relevance to diseases.

Authors:  Hadeel T Zedan; Fatma H Ali; Hatem Zayed
Journal:  Chromosoma       Date:  2022-07-30       Impact factor: 2.919

5.  The Impact of Variant Philadelphia Chromosome Translocations on the Clinical Course of Chronic Myeloid Leukemia.

Authors:  Damla Eyüpoğlu; Süreyya Bozkurt; İbrahim Haznedaroğlu; Yahya Büyükaşık; Deniz Güven
Journal:  Turk J Haematol       Date:  2016-03-05       Impact factor: 1.831

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.